<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: Additional ", fill: "#aaf0d1"},
{source: "4: Additional ", target: "4: uncertainties", fill: "#aaf0d1"},
{source: "4: uncertainties", target: "4: immaterial may also impair", fill: "#aaf0d1"},
{source: "4: immaterial may also impair", target: "4: operations", fill: "#aaf0d1"},
{source: "4: Additional ", target: "11: which cannot", fill: "#6e7f80"},
{source: "11: which cannot", target: "11: losses will continue as", fill: "#6e7f80"},
{source: "11: losses will continue as", target: "11: development activities", fill: "#6e7f80"},
{source: "11: which cannot", target: "16: development", fill: "#b666d2"},
{source: "16: development", target: "16: costs associated with clinical testing", fill: "#b666d2"},
{source: "16: costs associated with clinical testing", target: "16: product candidates", fill: "#b666d2"},
{source: "16: development", target: "44: candidates", fill: "#002147"},
{source: "44: candidates", target: "44: either by intravenous infusion", fill: "#002147"},
{source: "44: either by intravenous infusion", target: "44: intravitreal", fill: "#002147"},
{source: "44: intravitreal", target: "44: subcutaneous injections which", fill: "#002147"},
{source: "44: subcutaneous injections which", target: "44: generally less well", fill: "#002147"},
{source: "44: generally less well", target: "44: by patients than tablet", fill: "#002147"},
{source: "44: by patients than tablet", target: "44: capsule delivery", fill: "#002147"},
{source: "44: candidates", target: "56: others failure", fill: "#03a"},
{source: "56: others failure", target: "56: product candidate", fill: "#03a"},
{source: "56: product candidate", target: "56: demonstrate safety", fill: "#03a"},
{source: "56: demonstrate safety", target: "56: development", fill: "#03a"},
{source: "56: development", target: "56: connected with exposure", fill: "#03a"},
{source: "56: connected with exposure", target: "56: difficulty", fill: "#03a"},
{source: "56: difficulty", target: "56: clinical trial lack", fill: "#03a"},
{source: "56: clinical trial lack", target: "56: sufficient supplies", fill: "#03a"},
{source: "56: sufficient supplies", target: "56: investigators trial monitors", fill: "#03a"},
{source: "56: investigators trial monitors", target: "56: consultants", fill: "#03a"},
{source: "56: consultants", target: "56: trial subjects", fill: "#03a"},
{source: "56: trial subjects", target: "56: comply with", fill: "#03a"},
{source: "56: others failure", target: "88: manufacture", fill: "#1a1110"},
{source: "88: manufacture", target: "88: product candidates", fill: "#1a1110"},
{source: "88: product candidates", target: "88: commercial use", fill: "#1a1110"},
{source: "88: manufacture", target: "147: These ", fill: "#de5d83"},
{source: "147: These ", target: "147: developments may", fill: "#de5d83"},
{source: "147: developments may", target: "147: difficult", fill: "#de5d83"},
{source: "147: difficult", target: "147: directors", fill: "#de5d83"},
{source: "147: directors", target: "147: officers liability insurance", fill: "#de5d83"},
{source: "147: These ", target: "START_HERE", fill: "#de5d83"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Business_development">Business development</a></td>
      <td>Business development entails tasks and processes to develop and implement growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of whom 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Healing_Is_Difficult">Healing Is Difficult</a></td>
      <td>Healing Is Difficult is the second studio album by Australian singer and songwriter Sia. It was released in the United Kingdom on 9 July 2001 and in the United States on 28 May 2002.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_People">Difficult People</a></td>
      <td>Difficult People is an American dark comedy streaming television series created by Julie Klausner.  Klausner stars alongside Billy Eichner as two struggling and jaded comedians living in New York City; the duo seemingly hate everyone but each other.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Difficult_Woman">A Difficult Woman</a></td>
      <td>A Difficult Woman is an Australian television series which screened in 1998 on the ABC. The three part series starred Caroline Goodall, in the title role of a woman whose best friend is murdered and is determined to find out why. It was written by Nicholas Hammond and Steven Vidler and directed by Tony Tilse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Second-language_acquisition">Second-language acquisition</a></td>
      <td>Second-language acquisition (SLA), sometimes called second-language learning — otherwise referred to as L2 (language 2) acquisition, is the process by which people learn a second language. Second-language acquisition is also the scientific discipline devoted to studying that process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_Loves">Difficult Loves</a></td>
      <td>Difficult Loves (Italian: Gli amori difficili) is a 1970 short story collection by Italo Calvino. It concerns love and the difficulty of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_to_Cure">Difficult to Cure</a></td>
      <td>Difficult to Cure is the fifth studio album by the British hard rock band Rainbow, released in 1981. The album marked the further commercialization of the band's sound, with Ritchie Blackmore once describing at the time his appreciation of the band Foreigner.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/For_Love_or_Money_(2014_film)">For Love or Money (2014 film)</a></td>
      <td>For Love or Money (Chinese: 露水红颜) is a Chinese romance film based on Hong Kong novelist Amy Cheung's 2006 novel of the same name. The film was directed by Gao Xixi and starring Liu Yifei and Rain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Difficult_Couple">The Difficult Couple</a></td>
      <td>The Difficult Couple (Chinese: 难夫难妻; pinyin: Nànfū Nànqī), also translated as Die for Marriage, is a 1913 Chinese film. It is known for being the earliest Chinese feature film.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Globe_Sessions">The Globe Sessions</a></td>
      <td>The Globe Sessions is the third studio album by American singer-songwriter Sheryl Crow, released on September 21, 1998, in the United Kingdom and September 29, 1998, in the United States, then re-released in 1999. It was nominated for Album of the Year, Best Rock Album and Best Engineered Non-Classical Album at the 1999 Grammys, winning the latter two awards.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>REGENERON PHARMACEUTICALS INC      Item 1A   Risk Factors       We operate in an <font color="blue">environment</font> that involves a number of <font color="blue"><font color="blue">significant</font> risks</font> and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>We caution you to read the following risk factors, which have     affected,  and/or  in the <font color="blue">future could affect</font>, our business, operating     results, <font color="blue">financial condition</font>, and <font color="blue"><font color="blue">cash flow</font>s</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">risks described</font> below     include forward-looking statements, and actual events and our actual results     <font color="blue">may differ <font color="blue">substantially</font> from</font> those discussed in these forward-looking     statements</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not currently known to us or     that we currently deem <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue"><font color="blue">additional</font> risks</font> and <font color="blue">uncertainties</font> are <font color="blue">described under</font> other     captions in this report and should be considered by our investors</td>
    </tr>
    <tr>
      <td>Risks Related to Our Financial Results and Need for <font color="blue">Additional </font>Financing       We  have  had  a  history of operating losses and we may never achieve     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If we continue to incur operating losses, we may be unable to     continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>From  <font color="blue">inception on</font> January 8, 1988 through <font color="blue">December </font>31, 2005, we had a     <font color="blue">cumulative loss</font> of dlra585dtta3 million</td>
    </tr>
    <tr>
      <td>If we continue to incur operating losses     and fail to become a <font color="blue">profitable company</font>, we may be unable to continue our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have no products that are available for sale and do not know     when we will have <font color="blue">products available</font> for sale, if ever</td>
    </tr>
    <tr>
      <td>In the absence of     revenue from the sale of products or other sources, the amount, timing,     nature or source of <font color="blue">which cannot</font> be predicted, our <font color="blue">losses will continue as</font>     we conduct our research and <font color="blue"><font color="blue">development</font> <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>We currently receive     <font color="blue">contract <font color="blue">manufacturing</font> revenue from</font> our <font color="blue">agreement</font> with Merck and, until     June 30, 2005, we received <font color="blue">contract research</font> and <font color="blue"><font color="blue">development</font> revenue from</font>     our  <font color="blue">agreement</font>  with  The Procter &amp; Gamble Company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">agreement</font> with     Procter &amp; Gamble expired in June 2005 and our <font color="blue">agreement</font> with Merck will     expire before the end of 2006</td>
    </tr>
    <tr>
      <td>The expiration of these <font color="blue">agreement</font>s results in     a <font color="blue"><font color="blue">significant</font> loss</font> of revenue to the Company</td>
    </tr>
    <tr>
      <td>We will need <font color="blue"><font color="blue">additional</font> funding</font> in the future, which may not be available to     us,  and  <font color="blue">which may force us</font> to delay, reduce or eliminate our product     <font color="blue"><font color="blue">development</font> programs</font> or <font color="blue"><font color="blue">commercialization</font> efforts</font></td>
    </tr>
    <tr>
      <td>We will need to expend substantial resources for research and <font color="blue">development</font>,     including <font color="blue">costs associated with clinical testing</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We believe our <font color="blue">existing capital resources will enable us</font> to meet operating     needs through at least mid-2008; however, our projected <font color="blue">revenue may decrease</font>     or  our <font color="blue">expenses may increase</font> and that would lead to our capital being     <font color="blue">consumed <font color="blue">significant</font>ly</font> before such time</td>
    </tr>
    <tr>
      <td>We <font color="blue">will likely</font> require <font color="blue">additional</font>     financing in the future and we may not be able to raise such <font color="blue">additional</font>     funds</td>
    </tr>
    <tr>
      <td>If we are able to obtain <font color="blue">additional</font> financing through the sale of     equity or <font color="blue">convertible debt</font> securities, <font color="blue">such sales may</font> be dilutive to our     <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>Debt <font color="blue">financing <font color="blue">arrangements</font> may</font> require us to <font color="blue">pledge certain</font>     assets or <font color="blue">enter into covenants</font> that <font color="blue">would restrict</font> our business <font color="blue">activities</font>     or our ability to <font color="blue">incur further indebtedness</font> and may contain other terms     that  are not favorable to our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>If we are unable to raise     <font color="blue">sufficient funds</font> to complete the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font>, we     may face delay, reduction or <font color="blue">elimination</font> of our research and <font color="blue">development</font>     programs or preclinical or <font color="blue">clinical trials</font>, in which case our business,     <font color="blue">financial condition</font> or results of <font color="blue">operations</font> may be <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>10       _________________________________________________________________    [44]Table <font color="blue">of <font color="blue">Contents       </font></font>We have a <font color="blue"><font color="blue">significant</font> amount</font> of debt and may have insufficient cash to     satisfy our <font color="blue">debt service</font> and <font color="blue">re<font color="blue">payment <font color="blue">obligations</font></font></font></td>
    </tr>
    <tr>
      <td>In addition, the amount     of our <font color="blue">debt could impede</font> our <font color="blue">operations</font> and <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td>We have a <font color="blue"><font color="blue">significant</font> amount</font> of <font color="blue">convertible debt</font> and semi-annual interest     <font color="blue">payment <font color="blue">obligations</font></font></td>
    </tr>
    <tr>
      <td>This debt, unless converted to shares of our common     stock, will mature in October 2008</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">generate sufficient</font>     <font color="blue">cash flow</font> or otherwise obtain <font color="blue">funds necessary</font> to make required <font color="blue">payments on</font>     our debt</td>
    </tr>
    <tr>
      <td>Even if we are able to meet our <font color="blue">debt service</font> <font color="blue">obligations</font>, the     amount  of  debt  we already have <font color="blue">could hurt</font> our ability to obtain any     <font color="blue">necessary financing</font> in the future for working capital, capital <font color="blue">expenditures</font>,     debt  service  <font color="blue">requirements</font>  or  other purposes</td>
    </tr>
    <tr>
      <td>In addition, our debt     <font color="blue"><font color="blue">obligations</font> could</font> require us to use a substantial portion of cash to pay     principal and <font color="blue">interest on</font> our debt, instead of applying those funds to other     purposes, such as research and <font color="blue">development</font>, working capital, and capital     <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>We have adopted, <font color="blue">effective</font> January 1, 2005, the <font color="blue">fair <font color="blue">market value</font> based</font>     method  of <font color="blue">accounting</font> for stock-based employee compensation</td>
    </tr>
    <tr>
      <td>This will     <font color="blue"><font color="blue">materially</font> increase</font> operating expenses in our Statement of Operations,     <font color="blue">primarily due</font> to non-cash compensation costs related to <font color="blue">stock options</font></td>
    </tr>
    <tr>
      <td>We have adopted, <font color="blue">effective</font> January 1, 2005, the <font color="blue"><font color="blue">fair value</font> based method</font> of     <font color="blue">accounting</font> for stock-based employee compensation under the provisions of     Statement of Financial <font color="blue">Accounting </font>Standards Nodtta (SFAS) 123, <font color="blue">Accounting </font>for     Stock Based Compensation, using the <font color="blue">modified prospective method as described</font>     in  SFAS 148, <font color="blue">Accounting </font>for <font color="blue">Stock Based Compensation </font>— Transition and     Disclosure</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">effective</font> January 1, 2005, we have been recognizing     expense  in  an amount equal to the <font color="blue">fair value</font> of share-based payments     (including stock option awards) on their date of <font color="blue">grant over</font> the vesting     period of the awards</td>
    </tr>
    <tr>
      <td>In 2005, non-cash stock-based employee compensation     expense of dlra19dtta9 million related to <font color="blue">stock options</font> awards was recognized in     operating expenses in our Statement of Operations, <font color="blue">which increased</font> our basic     and <font color="blue">diluted net loss per</font> share</td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">December </font>2004, the Financial <font color="blue">Accounting </font>Standards Board     issued SFAS 123R, Share-Based Payment, which is a revision of SFAS 123 and     supersedes <font color="blue">Accounting </font>Principles Board Nodtta 25, <font color="blue">Accounting </font>for Stock Issued     to Employees</td>
    </tr>
    <tr>
      <td>SFAS 123R requires the <font color="blue">recognition</font> of <font color="blue">compensation expense</font> in     an amount equal to the <font color="blue">fair value</font> of share-based payments (including stock     options) issued to employees</td>
    </tr>
    <tr>
      <td>We are required to adopt SFAS 123R <font color="blue">effective</font>     for  the <font color="blue">fiscal year beginning</font> January 1, 2006</td>
    </tr>
    <tr>
      <td>The impact of adopting     SFAS 123R has not <font color="blue">yet been quantified</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">negative impact on</font> our income (loss) as a result of adopting SFAS 123 as     of  January 1,  2005,  and  <font color="blue">subsequently adopting</font> SFAS 123R commencing     January 1, 2006, may negatively affect our stock price</td>
    </tr>
    <tr>
      <td>Risks Related to Development of Our Product Candidates       Successful <font color="blue">development</font> of any of our <font color="blue">product <font color="blue">candidates</font></font> is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>Only a small minority of all research and <font color="blue"><font color="blue">development</font> programs</font> ultimately     result in <font color="blue">commercially</font> successful drugs</td>
    </tr>
    <tr>
      <td>We have never developed a drug that     has  <font color="blue">been approved</font> for marketing and sale, and we may never succeed in     developing an <font color="blue">approved drug</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">clinical trials</font> <font color="blue">demonstrate</font> safety and     <font color="blue">effective</font>ness of any of our <font color="blue">product <font color="blue">candidates</font></font> for a <font color="blue">specific disease</font> and     the <font color="blue">necessary <font color="blue"><font color="blue">regulatory</font> approval</font>s</font> are obtained, the <font color="blue">commercial success</font> of     any of our <font color="blue">product <font color="blue">candidates</font></font> will depend upon their <font color="blue">acceptance by patients</font>,     the <font color="blue">medical community</font>, and third-party payers and on our partners’ ability     to <font color="blue"><font color="blue">successfully</font> <font color="blue">manufacture</font></font> and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our     product  <font color="blue">candidates</font> are delivered <font color="blue">either by intravenous infusion</font> or by     <font color="blue">intravitreal</font> or subcutaneous injections, which are <font color="blue"><font color="blue">generally</font> less well</font>     received <font color="blue">by patients than tablet</font> or <font color="blue">capsule delivery</font></td>
    </tr>
    <tr>
      <td>If our products are     not  <font color="blue">successfully</font>  <font color="blue">commercialize</font>d,  we will not be able to recover the     <font color="blue"><font color="blue">significant</font> investment</font> we have made in developing <font color="blue">such products</font> and our     business would be <font color="blue"><font color="blue">severely harm</font>ed</font></td>
    </tr>
    <tr>
      <td>We  intend  to  study our lead <font color="blue">product <font color="blue">candidates</font></font>, the VEGF Trap, VEGF     Trap-Eye, and IL-1 Trap, in a wide variety of <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>We intend to     study <font color="blue">the VEGF Trap </font>in a variety of <font color="blue">cancer settings</font>, the VEGF Trap-Eye in     <font color="blue">different</font> <font color="blue">eye diseases</font> and <font color="blue">ophthalmologic</font> <font color="blue"><font color="blue">indication</font>s</font>, and the IL-1 Trap in     a variety of systemic <font color="blue">inflammatory</font>                                         11       _________________________________________________________________    [45]Table <font color="blue">of <font color="blue">Contents       </font></font>disorders</td>
    </tr>
    <tr>
      <td>Most of these current trials are <font color="blue">exploratory</font> studies designed to     identify what diseases and uses, if any, are best suited for our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>It is likely that our <font color="blue">product <font color="blue">candidates</font></font> will not <font color="blue">demonstrate</font>     the  requisite  efficacy  and/or  safety  profile to <font color="blue">support continued</font>     <font color="blue">development</font> for most of the <font color="blue"><font color="blue">indication</font>s</font> that are to be studied</td>
    </tr>
    <tr>
      <td>In fact, our     <font color="blue">product <font color="blue">candidates</font></font> may not <font color="blue">demonstrate</font> the <font color="blue">requisite efficacy</font> and safety     profile to support the continued <font color="blue">development</font> for any of the <font color="blue"><font color="blue">indication</font>s</font> or     uses</td>
    </tr>
    <tr>
      <td><font color="blue">Clinical  </font>trials required for our <font color="blue">product <font color="blue">candidates</font></font> are expensive and     time-consuming, and their outcome is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>If any of our drug     trials are delayed or achieve unfavorable results, we will have to delay or     may be unable to obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">must conduct</font> extensive testing of our <font color="blue">product <font color="blue">candidates</font></font> before we can     obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to market and sell them</td>
    </tr>
    <tr>
      <td>We need to <font color="blue">conduct both</font>     <font color="blue">preclinical animal testing</font> and human <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Conducting </font>these     trials is a lengthy, time-consuming, and <font color="blue">expensive process</font></td>
    </tr>
    <tr>
      <td>These tests and     trials may not achieve favorable results for many reasons, including, among     others, failure of the <font color="blue">product candidate</font> to <font color="blue">demonstrate</font> safety or efficacy,     the <font color="blue">development</font> of serious or life-threatening adverse events (or side     effects) caused by or <font color="blue">connected with exposure</font> to the <font color="blue">product candidate</font>,     <font color="blue"><font color="blue">difficult</font>y</font> in enrolling and maintaining subjects in the clinical trial, lack     of <font color="blue">sufficient supplies</font> of the <font color="blue">product candidate</font>, and the failure of clinical     investigators, trial monitors and other <font color="blue">consultants</font>, or <font color="blue">trial subjects</font> to     <font color="blue">comply with</font> the trial plan or protocol</td>
    </tr>
    <tr>
      <td>A <font color="blue">clinical trial may fail</font> because it     did not include a sufficient number of patients to detect the endpoint being     measured or <font color="blue">reach statistical significance</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">clinical trial may also fail</font>     because the dose(s) of the <font color="blue">investigational drug</font> included in the trial were     either  too  low  or  too  high to determine the optimal effect of the     <font color="blue">investigational drug</font> in the <font color="blue">disease setting</font></td>
    </tr>
    <tr>
      <td>For example, we are studying     <font color="blue">higher doses</font> of the IL-1 Trap in <font color="blue">different</font> diseases after a phase 2 trial     using lower doses of the IL-1 Trap in subjects with rheumatoid arthritis     failed to achieve its primary endpoint</td>
    </tr>
    <tr>
      <td>We will need to reevaluate any <font color="blue">drug candidate</font> that does not <font color="blue">test favorably</font>     and either conduct new trials, which are expensive and time consuming, or     abandon the drug <font color="blue">development</font> program</td>
    </tr>
    <tr>
      <td>Even if we obtain positive results     <font color="blue">from preclinical</font> or <font color="blue">clinical trials</font>, we may not achieve the <font color="blue">same success</font> in     <font color="blue">future trials</font></td>
    </tr>
    <tr>
      <td>Many companies in the <font color="blue"><font color="blue">bio<font color="blue">pharmaceutical</font></font> industry</font>, including     us,  have <font color="blue">suffered <font color="blue">significant</font> setbacks</font> in <font color="blue">clinical trials</font>, even after     promising results have been obtained in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>The failure of     <font color="blue">clinical trials</font> to <font color="blue">demonstrate</font> safety and <font color="blue">effective</font>ness for the desired     <font color="blue">indication</font>(s) <font color="blue">could harm</font> the <font color="blue">development</font> of the <font color="blue">product candidate</font>(s), and     our  business,  financial  condition, and results of <font color="blue">operations</font> may be     <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of serious or life-threatening side <font color="blue">effects with</font> any of our     <font color="blue">product <font color="blue">candidates</font></font> would lead to delay or <font color="blue">discontinuation</font> of <font color="blue">development</font>,     <font color="blue"><font color="blue">which could</font> <font color="blue">severely harm</font></font> our business</td>
    </tr>
    <tr>
      <td>During the conduct of <font color="blue">clinical trials</font>, patients report changes in their     health, including illnesses, injuries, and <font color="blue">discomforts</font>, to their study     doctor</td>
    </tr>
    <tr>
      <td>Often, it is not possible to determine whether or not the drug     candidate  being  studied  caused these <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>Various illnesses,     injuries,  and <font color="blue">discomforts</font> have been reported from time-to-time during     clinical  trials  of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Although our <font color="blue">current drug</font>     <font color="blue">candidates</font>  appeared to be <font color="blue"><font color="blue">generally</font> well tolerated</font> in <font color="blue">clinical trials</font>     conducted to date, it is <font color="blue">possible as</font> we test any of them in larger, longer,     and more extensive <font color="blue">clinical programs</font>, illnesses, injuries, and <font color="blue">discomforts</font>     that were observed in <font color="blue">earlier trials</font>, as well as <font color="blue">conditions</font> that did not     occur or <font color="blue">went undetected</font> in smaller previous trials, will be reported by     patients</td>
    </tr>
    <tr>
      <td>Many times, side effects are <font color="blue">only detectable</font> after investigational     drugs are tested in large scale, phase 3 <font color="blue">clinical trials</font> or, in some cases,     after they are made available to patients after approval</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional</font>     clinical experience indicates that any of our <font color="blue">product <font color="blue">candidates</font></font> has many     side  effects  or causes serious or life-threatening side effects, the     <font color="blue">development</font> of the <font color="blue">product candidate</font> may fail or be delayed, which would     <font color="blue">severely harm</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Our VEGF Trap </font>is being studied for the <font color="blue">potential treatment</font> of <font color="blue">certain types</font>     of cancer and our VEGF Trap-Eye candidate is being studied in diseases of     the  eye</td>
    </tr>
    <tr>
      <td>There  are  many  <font color="blue">potential safety concerns associated with</font>     <font color="blue"><font color="blue">significant</font> blockade</font> of <font color="blue">vascular endothelial growth</font> factor, or VEGF <font color="blue">These     </font>risks, based on the clinical and preclinical experience of <font color="blue">systemically</font>     delivered VEGF <font color="blue">inhibitors</font>, including the <font color="blue">systemic delivery</font> of the VEGF Trap,     include bleeding, hypertension, and proteinuria</td>
    </tr>
    <tr>
      <td>These serious side effects     and other serious side effects have been reported in our systemic <font color="blue">VEGF Trap     </font>studies in cancer and diseases of the eye</td>
    </tr>
    <tr>
      <td>In addition, patients given     infusions  of  any  protein, including <font color="blue">the VEGF Trap </font>delivered through     intravenous <font color="blue">administration</font>, may develop <font color="blue">severe hypersensitivity reactions</font>,     referred to <font color="blue">as infusion reactions</font></td>
    </tr>
    <tr>
      <td>These and other <font color="blue">complications</font> or side     effects                                         12       _________________________________________________________________    [46]Table <font color="blue">of <font color="blue">Contents       </font></font><font color="blue">could harm</font> the <font color="blue">development</font> of <font color="blue">the VEGF Trap </font>for the treatment of cancer or     the VEGF Trap-Eye for the treatment of diseases of the eye</td>
    </tr>
    <tr>
      <td>Although the IL-1 Trap was <font color="blue"><font color="blue">generally</font> well tolerated</font> and was not associated     with any drug-related serious adverse events in the phase 2 rheumatoid     <font color="blue">arthritis study</font> completed in 2003, safety or <font color="blue">tolerability concerns may</font> arise     as we test <font color="blue">higher doses</font> of the IL-1 Trap in patients with other <font color="blue">inflammatory</font>     diseases and disorders</td>
    </tr>
    <tr>
      <td>Like TNF-<font color="blue">antagonist</font>s such as Enbrel^®(Amgen) and     Remicade^® (Centocor), the IL-1 Trap affects the <font color="blue">immune defense system</font> of     the body by blocking some of its functions</td>
    </tr>
    <tr>
      <td>Therefore, there may be an     increased risk for <font color="blue">infections</font> to develop in <font color="blue">patients treated with</font> the IL-1     Trap</td>
    </tr>
    <tr>
      <td>In addition, patients given infusions of the IL-1 Trap have developed     hypersensitivity reactions, referred to <font color="blue">as infusion reactions</font></td>
    </tr>
    <tr>
      <td>These and     other <font color="blue">complications</font> or side effects <font color="blue">could harm</font> the <font color="blue">development</font> of the IL-1     Trap</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">development</font> are <font color="blue">recombinant proteins</font> that could     cause  an  immune  response,  resulting  in the creation of harmful or     <font color="blue">neutralizing <font color="blue"><font color="blue">antibodies</font> against</font></font> the <font color="blue"><font color="blue">therapeutic</font> protein</font></td>
    </tr>
    <tr>
      <td>In addition to the safety, efficacy, <font color="blue">manufacturing</font>, and <font color="blue"><font color="blue">regulatory</font> hurdles</font>     <font color="blue">faced by</font> our <font color="blue">product <font color="blue">candidates</font></font>, the <font color="blue">administration</font> of <font color="blue">recombinant proteins</font>     <font color="blue">frequently</font>  causes  an  immune  response, resulting in the creation of     <font color="blue"><font color="blue">antibodies</font> against</font> the <font color="blue"><font color="blue">therapeutic</font> protein</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">antibodies</font> can have no     effect  or can totally neutralize the <font color="blue">effective</font>ness of the protein, or     require that <font color="blue">higher doses</font> be used to obtain a <font color="blue">therapeutic</font> effect</td>
    </tr>
    <tr>
      <td>In some     cases,  the  antibody can <font color="blue">cross react with</font> the patient’s own proteins,     resulting in an “auto-immune” type disease</td>
    </tr>
    <tr>
      <td>Whether <font color="blue">antibodies</font> will be     created can often not be predicted <font color="blue">from preclinical</font> or <font color="blue">clinical experiments</font>,     and their appearance is <font color="blue">often delayed</font>, so that there can be no assurance     that neutralizing <font color="blue">antibodies</font> will not be created at a later date — in some     <font color="blue">cases even</font> after pivotal <font color="blue">clinical trials</font> have been completed</td>
    </tr>
    <tr>
      <td>Subjects who     received the IL-1 Trap in <font color="blue">clinical trials</font> have developed <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>It is     possible  that  as we test <font color="blue">the VEGF Trap </font>with more <font color="blue">sensitive assays</font> in     <font color="blue">different</font> patient populations and larger <font color="blue">clinical trials</font>, we will find that     <font color="blue">subjects given</font> <font color="blue">the VEGF Trap </font>develop <font color="blue">antibodies</font> to the <font color="blue">product candidate</font></td>
    </tr>
    <tr>
      <td>We may be unable to formulate or <font color="blue">manufacture</font> our <font color="blue">product <font color="blue">candidates</font></font> in a way     that is suitable for clinical or <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>Changes in product <font color="blue"><font color="blue">formulation</font>s</font> and <font color="blue">manufacturing</font> processes may be required     as <font color="blue">product <font color="blue">candidates</font></font> progress in clinical <font color="blue">development</font> and are ultimately     <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>If we are unable to develop suitable product <font color="blue"><font color="blue">formulation</font>s</font> or     <font color="blue">manufacturing</font> processes to support large <font color="blue">scale clinical testing</font> of our     <font color="blue">product <font color="blue">candidates</font></font>, including the VEGF Trap, VEGF Trap-Eye, IL-1 Trap, and     IL-4/13  Trap,  we may be unable to <font color="blue">supply necessary materials</font> for our     clinical  trials,  which  would  delay  the <font color="blue">development</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Similarly, if we are unable to <font color="blue"><font color="blue">supply sufficient</font> quantities</font> of     our product or develop product <font color="blue"><font color="blue">formulation</font>s</font> suitable for <font color="blue">commercial use</font>, we     will not be able to <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Risks Related to Intellectual Property       If we <font color="blue">cannot protect</font> the <font color="blue">confidentiality</font> of our <font color="blue">trade secrets</font> or our patents     are  insufficient  to protect our <font color="blue"><font color="blue">proprietary</font> rights</font>, our business and     <font color="blue"><font color="blue"><font color="blue">competitive</font> position</font> will</font> be harmed</td>
    </tr>
    <tr>
      <td>Our business requires <font color="blue">using sensitive</font> and <font color="blue"><font color="blue">proprietary</font> technology</font> and other     information that we protect as <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We seek to <font color="blue">prevent improper</font>     <font color="blue">disclosure</font> of these <font color="blue">trade secrets</font> through <font color="blue">confidentiality</font> <font color="blue">agreement</font>s</td>
    </tr>
    <tr>
      <td>If our     <font color="blue">trade secrets</font> are improperly exposed, either by our own employees or our     <font color="blue">collaborators</font>,  it would help our <font color="blue">competitors</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our     business</td>
    </tr>
    <tr>
      <td>We  will  be  able  to  protect our <font color="blue"><font color="blue">proprietary</font> rights</font> from     <font color="blue">unauthorized use by <font color="blue">third parties</font> only</font> to the extent that our rights are     <font color="blue">covered by valid</font> and <font color="blue">enforceable patents</font> or are <font color="blue">effective</font>ly maintained as     <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of <font color="blue"><font color="blue">biotechnology</font> companies involves</font>     <font color="blue">complex legal</font> and factual questions and, therefore, enforceability cannot be     <font color="blue">predicted with certainty</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patents may</font> be challenged, invalidated, or     <font color="blue">circumvented</font></td>
    </tr>
    <tr>
      <td>Patent <font color="blue">applications filed outside</font> the <font color="blue">United States </font>may be     challenged  by  third  parties who file an opposition</td>
    </tr>
    <tr>
      <td>Such opposition     <font color="blue">proceedings</font> are <font color="blue">increasingly common</font> in the <font color="blue">European Union </font>and are costly to     defend</td>
    </tr>
    <tr>
      <td>We have <font color="blue">patent applications</font> that are being opposed and it is likely     that we will need to defend <font color="blue">additional</font> <font color="blue">patent applications</font> in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent rights may</font> not <font color="blue">provide us with</font> a <font color="blue"><font color="blue">proprietary</font> position</font> or                                         13       _________________________________________________________________    [47]Table <font color="blue">of <font color="blue">Contents       </font></font><font color="blue">competitive</font> <font color="blue">advantages</font> against <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>Furthermore, even if the outcome     is favorable to us, the <font color="blue">enforcement</font> of our <font color="blue">intellectual property rights</font> can     be <font color="blue">extremely expensive</font> and time consuming</td>
    </tr>
    <tr>
      <td>We may be restricted in our <font color="blue">development</font> and/or <font color="blue">commercialization</font> <font color="blue">activities</font>     by, and could be subject to <font color="blue"><font color="blue">damage award</font>s</font> if we are found to have infringed,     <font color="blue"><font color="blue">third party</font> patents</font> or other <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">commercial success</font> depends <font color="blue">significant</font>ly on our ability to operate     without  infringing  the patents and other <font color="blue"><font color="blue">proprietary</font> rights</font> of third     parties</td>
    </tr>
    <tr>
      <td>Other <font color="blue">parties may</font> allege that they have <font color="blue">blocking patents</font> to our     products  in  clinical  <font color="blue">development</font>, either because they claim to hold     <font color="blue">proprietary</font>  rights  to  the <font color="blue">composition</font> of a product or the way it is     <font color="blue">manufacture</font>d or used</td>
    </tr>
    <tr>
      <td>We are aware of patents and <font color="blue"><font color="blue">pending application</font>s</font> owned by <font color="blue">Genentech </font>that     claim  <font color="blue">certain chimeric</font> VEGF receptor <font color="blue">composition</font>s</td>
    </tr>
    <tr>
      <td>Although we do not     believe that <font color="blue">the VEGF Trap </font>or VEGF Trap-Eye infringes any valid claim in     these patents or <font color="blue">patent applications</font>, <font color="blue">Genentech </font><font color="blue">could initiate</font> a lawsuit for     <font color="blue">patent <font color="blue">infringement</font></font> and assert its patents are valid and cover the <font color="blue">VEGF Trap     </font>or VEGF Trap-Eye</td>
    </tr>
    <tr>
      <td><font color="blue">Genentech </font>may be motivated to initiate such a <font color="blue">lawsuit at</font>     some point in an effort to impair our ability to develop and sell the VEGF     Trap or VEGF Trap-Eye, <font color="blue">which represents</font> a <font color="blue">potential <font color="blue">competitive</font> threat</font> to     Genentech’s  VEGF-binding  products and <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>An adverse     <font color="blue">determination by</font> a court in any <font color="blue">such potential patent <font color="blue">litigation</font> would</font>     <font color="blue">likely <font color="blue">materially</font> harm</font> our business by requiring us to seek a license, which     may not be available, or resulting in our <font color="blue">inability</font> to <font color="blue">manufacture</font>, develop     and sell <font color="blue">the VEGF Trap </font>or VEGF Trap-Eye or in a <font color="blue">damage award</font></td>
    </tr>
    <tr>
      <td>We  are aware of certain <font color="blue">United States </font>and foreign patents relating to     particular IL-4 and IL-13 <font color="blue">receptors</font></td>
    </tr>
    <tr>
      <td>Our IL-4/13 Trap includes portions of     the IL-4 and IL-13 <font color="blue">receptors</font></td>
    </tr>
    <tr>
      <td>In addition, we are aware of a <font color="blue">broad patent</font>     held by <font color="blue">Genentech </font>relating to <font color="blue">proteins fused</font> to <font color="blue">certain immunoglobulin</font>     domains</td>
    </tr>
    <tr>
      <td>Our  Trap  product  <font color="blue">candidates</font>  include  proteins  fused  to     <font color="blue">immunoglobulin domains</font></td>
    </tr>
    <tr>
      <td>Although we do not believe that we are infringing     valid and enforceable <font color="blue"><font color="blue">third party</font> patents</font>, the holders of these <font color="blue">patents may</font>     sue us for <font color="blue">infringement</font> and a <font color="blue">court may find</font> that we are <font color="blue">infringing one</font> or     more validly issued patents, which may <font color="blue">materially</font> harm our business</td>
    </tr>
    <tr>
      <td>Any <font color="blue">patent holders could sue us</font> for damages and seek to <font color="blue">prevent us from</font>     <font color="blue">manufacturing</font>, selling, or developing our drug <font color="blue">candidates</font>, and a court may     find that we are <font color="blue">infringing validly issued patents</font> of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In the     event that the <font color="blue">manufacture</font>, use, or sale of any of our clinical <font color="blue">candidates</font>     <font color="blue">infringes on</font> the patents or violates other <font color="blue"><font color="blue">proprietary</font> rights</font> of third     parties,  we  may  be  prevented  from  pursuing  product <font color="blue">development</font>,     <font color="blue">manufacturing</font>, and <font color="blue">commercialization</font> of our drugs and may be required to pay     <font color="blue">costly damages</font></td>
    </tr>
    <tr>
      <td>Such a result may <font color="blue">materially</font> harm our business, financial     condition, and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We seek to obtain licenses to patents when, in our judgment, such licenses     are needed</td>
    </tr>
    <tr>
      <td>If any licenses are required, we may not be able to obtain such     licenses on <font color="blue">commercially</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>The failure to obtain     any such license could <font color="blue">prevent us from</font> developing or <font color="blue">commercializing</font> any one     or more of our <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue"><font color="blue">which could</font> <font color="blue">severely harm</font></font> our business</td>
    </tr>
    <tr>
      <td>Regulatory and Litigation Risks       If we do not obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">product <font color="blue">candidates</font></font>, we will     not be able to market or sell them</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot sell</font> or market products without <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>If we do not     obtain and maintain <font color="blue"><font color="blue">regulatory</font> approval</font> for our <font color="blue">product <font color="blue">candidates</font></font>, the     value of our company and our results of <font color="blue">operations</font> will be harmed</td>
    </tr>
    <tr>
      <td>In the     United States, we must obtain and maintain <font color="blue">approval from</font> the <font color="blue">United States </font>    Food  and  Drug  Administration (FDA) for each drug we intend to sell</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining FDA </font>approval is typically a lengthy and <font color="blue">expensive process</font>, and     approval  is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>Foreign <font color="blue"><font color="blue">government</font>s also regulate drugs</font>     <font color="blue">distributed</font> in their country and approval in any country is likely to be a     lengthy and <font color="blue">expensive process</font>, and approval is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>None of our     <font color="blue">product <font color="blue">candidates</font></font> has ever received <font color="blue"><font color="blue">regulatory</font> approval</font> to be marketed and     sold  in  the <font color="blue">United States </font>or any other country</td>
    </tr>
    <tr>
      <td>We may never receive     <font color="blue"><font color="blue">regulatory</font> approval</font> for any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________    [48]Table <font color="blue">of <font color="blue">Contents       </font></font>If the testing or use of our products harms people, we could be subject to     costly and damaging product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also face costly</font> and     damaging claims arising from employment law, securities law, <font color="blue">environment</font>al     law, or other <font color="blue">applicable laws governing</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The testing, <font color="blue">manufacturing</font>, marketing, and sale of drugs for use in people     expose  us  to product <font color="blue">liability</font> risk</td>
    </tr>
    <tr>
      <td>Any <font color="blue">informed consent</font> or waivers     obtained from people who sign up for our <font color="blue">clinical trials</font> may not <font color="blue">protect us</font>     from <font color="blue">liability</font> or the cost of <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">liability</font> insurance     may not cover all <font color="blue">potential liabilities</font> or may not <font color="blue">completely cover</font> any     <font color="blue">liability</font> arising from any such <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Moreover, we may not have access     to <font color="blue">liability</font> insurance or be able to maintain our <font color="blue">insurance on</font> acceptable     terms</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">operations</font>  may  involve  <font color="blue">hazardous</font>  materials and are subject to     <font color="blue">environment</font>al,  health,  and <font color="blue">safety laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We may incur     substantial <font color="blue">liability</font> arising from our <font color="blue">activities</font> involving the use of     <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>As a <font color="blue">bio<font color="blue">pharmaceutical</font></font> company with <font color="blue">significant</font> <font color="blue">manufacturing</font> <font color="blue">operations</font>, we     are  subject  to  extensive <font color="blue">environment</font>al, health, and <font color="blue">safety laws</font> and     <font color="blue">regulations</font>, including those governing the use of <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>Our     research and <font color="blue">development</font> and <font color="blue">manufacturing</font> <font color="blue">activities</font> involve the controlled     use  of chemicals, viruses, radioactive compounds, and other <font color="blue">hazardous</font>     materials</td>
    </tr>
    <tr>
      <td>The cost of <font color="blue">compliance with</font> <font color="blue">environment</font>al, health, and safety     <font color="blue">regulations</font> is substantial</td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> involving these materials or an     <font color="blue">environment</font>al discharge were to occur, we could be held liable for any     resulting  damages, or face <font color="blue">regulatory</font> actions, <font color="blue">which could</font> exceed our     resources or <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>Changes in the <font color="blue">securities laws</font> and <font color="blue">regulations</font> have increased, and are     likely to continue to increase, our costs</td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002, which became law in July 2002, has required     changes in some of our corporate governance, securities <font color="blue">disclosure</font>, and     <font color="blue">compliance practices</font></td>
    </tr>
    <tr>
      <td>In response to the <font color="blue">requirements</font> of that Act, <font color="blue">the SEC     </font>and the NASDAQ Stock Market have <font color="blue">promulgated new rules</font> and <font color="blue">listing standards</font>     covering a variety of subjects</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with these new rules and listing     standards has increased our <font color="blue">legal costs</font>, and <font color="blue">significant</font>ly increased our     <font color="blue">accounting</font> and <font color="blue">auditing costs</font>, and we expect these costs to continue</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">development</font>s may make it more <font color="blue">difficult</font> and more expensive for us to obtain     <font color="blue">directors</font>’ and officers’ <font color="blue">liability</font> insurance</td>
    </tr>
    <tr>
      <td>Likewise, these <font color="blue">development</font>s     may make it more <font color="blue">difficult</font> for us to attract and retain qualified members of     our board of <font color="blue">directors</font>, <font color="blue">particularly</font> independent <font color="blue">directors</font>, or qualified     <font color="blue">executive officers</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">future years</font>, if we or our independent registered public <font color="blue">accounting</font> firm     are unable to conclude that our <font color="blue">internal control over financial</font> reporting is     <font color="blue">effective</font>, the <font color="blue">market value</font> of our <font color="blue"><font color="blue">common stock</font> could</font> be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>As  <font color="blue">directed by</font> Section 404 of the Sarbanes-Oxley Act of 2002, <font color="blue">the SEC     </font><font color="blue">adopted rules</font> requiring <font color="blue">public companies</font> to include a report of <font color="blue">management</font>     on the Company’s <font color="blue">internal control over financial</font> reporting in their annual     reports  on Form 10-K that contains an <font color="blue">assessment</font> by <font color="blue">management</font> of the     <font color="blue">effective</font>ness of our <font color="blue">internal control over financial</font> reporting</td>
    </tr>
    <tr>
      <td>In addition,     the independent registered public <font color="blue">accounting</font> firm auditing our financial     <font color="blue">statements must attest</font> to and report on <font color="blue">management</font>’s <font color="blue">assessment</font> and on the     <font color="blue">effective</font>ness  of  our  <font color="blue">internal control over financial</font> reporting</td>
    </tr>
    <tr>
      <td>Our     independent  registered  public  <font color="blue">accounting</font>  firm  <font color="blue">provided us with</font> an     unqualified  report  as to our <font color="blue">assessment</font> and the <font color="blue">effective</font>ness of our     <font color="blue">internal control over financial</font> reporting as of <font color="blue">December </font>31, 2005, which     report is included in this <font color="blue">Annual Report </font>on Form 10-K for the year ended     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font> you that <font color="blue">management</font> or our     independent registered public <font color="blue">accounting</font> firm will be able to <font color="blue">provide such</font>     an <font color="blue">assessment</font> or unqualified report as of future year-ends</td>
    </tr>
    <tr>
      <td>In this event,     investors  could  lose  confidence in the re<font color="blue">liability</font> of our financial     statements, <font color="blue">which could</font> result in a decrease in the <font color="blue">market value</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [49]Table <font color="blue">of <font color="blue">Contents       </font></font>Risks Related to Our Dependence on Third Parties       If our <font color="blue">collaboration</font> with sanofi-aventis for <font color="blue">the VEGF Trap </font>is terminated,     our  business  <font color="blue">operations</font> and our ability to develop, <font color="blue">manufacture</font>, and     <font color="blue">commercialize</font>  <font color="blue">the VEGF Trap </font>in the time expected, or at all, would be     harmed</td>
    </tr>
    <tr>
      <td>We rely heavily on sanofi-aventis to <font color="blue">assist with</font> the <font color="blue">development</font> of the VEGF     Trap <font color="blue">oncology program</font></td>
    </tr>
    <tr>
      <td>Sanofi-aventis funds all of the <font color="blue">development</font> expenses     incurred  by  <font color="blue">both companies</font> in <font color="blue">connection with</font> <font color="blue">the VEGF Trap </font>oncology     program</td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the VEGF Trap </font></font><font color="blue">oncology program</font> continues, we <font color="blue">will rely on</font>     sanofi-aventis  to  <font color="blue">assist with</font> funding <font color="blue">the VEGF Trap </font>program, provide     commercial <font color="blue">manufacturing</font> capacity, enroll and monitor <font color="blue">clinical trials</font>,     obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, <font color="blue">particularly</font> outside the United States, and     provide sales and marketing support</td>
    </tr>
    <tr>
      <td>While we <font color="blue">cannot assure</font> you that the     VEGF  Trap  will ever be <font color="blue">successfully</font> developed and <font color="blue">commercialize</font>d, if     sanofi-aventis does not perform its <font color="blue">obligations</font> in a <font color="blue">timely manner</font>, or at     all, our ability to develop, <font color="blue">manufacture</font>, and <font color="blue">commercialize</font> <font color="blue">the VEGF Trap </font>in     cancer <font color="blue"><font color="blue">indication</font>s</font> will be <font color="blue">significant</font>ly <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Sanofi-aventis     has the right to terminate its <font color="blue">collaboration</font> <font color="blue">agreement</font> with us at any time     <font color="blue">upon twelve months advance</font> notice</td>
    </tr>
    <tr>
      <td>If sanofi-aventis were to terminate its     <font color="blue">collaboration</font> <font color="blue">agreement</font> with us, we would not have the resources or skills     to replace those of our partner, <font color="blue">which could</font> cause <font color="blue">significant</font> delays in the     <font color="blue">development</font> and/or <font color="blue">manufacture</font> of <font color="blue">the VEGF Trap </font>and result in substantial     <font color="blue">additional</font>  costs  to us</td>
    </tr>
    <tr>
      <td>We have no sales, marketing, or <font color="blue">distribution</font>     <font color="blue">capabilities</font> and would have to develop or outsource these <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Termination </font>of the sanofi-aventis <font color="blue">collaboration</font> <font color="blue">agreement</font> would create     substantial new and <font color="blue"><font color="blue">additional</font> risks</font> to the successful <font color="blue">development</font> of the     VEGF Trap <font color="blue">oncology program</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> and <font color="blue">service providers may fail</font> to perform <font color="blue">adequately</font> in     their efforts to support the <font color="blue">development</font>, <font color="blue">manufacture</font>, and <font color="blue">commercialization</font>     of our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We depend upon third-party <font color="blue">collaborators</font>, including sanofi-aventis and     service providers such as clinical research <font color="blue"><font color="blue">organization</font>s</font>, outside testing     laboratories, clinical investigator sites, and third-party <font color="blue">manufacture</font>rs and     product <font color="blue">packagers</font> and labelers, to <font color="blue">assist us</font> in the <font color="blue">development</font> of our     product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If  any of our existing <font color="blue">collaborators</font> or service     <font color="blue">providers breaches</font> or terminates its <font color="blue">agreement</font> with us or does not perform     its <font color="blue">development</font> or <font color="blue">manufacturing</font> services under an <font color="blue">agreement</font> in a timely     manner  or  at  all, we could experience <font color="blue">additional</font> costs, delays, and     <font color="blue">difficult</font>ies in the <font color="blue">development</font> or ultimate <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Risks Related to the Manufacture of Our Product Candidates       We have limited <font color="blue">manufacturing</font> capacity, <font color="blue">which could</font> inhibit our ability to     <font color="blue">successfully</font> develop or <font color="blue">commercialize</font> our drugs</td>
    </tr>
    <tr>
      <td>Before approving a new drug or <font color="blue">biologic product</font>, the FDA requires that the     <font color="blue"><font color="blue">facilities</font> at which</font> the <font color="blue">product will</font> be <font color="blue">manufacture</font>d be in <font color="blue">compliance with</font>     current good <font color="blue">manufacturing</font> practices, or cGMP <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing     </font><font color="blue">product <font color="blue">candidates</font></font> in <font color="blue">compliance with</font> these <font color="blue">regulatory</font> <font color="blue">requirements</font> is     complex, time-consuming, and expensive</td>
    </tr>
    <tr>
      <td>To be successful, our <font color="blue">products must</font>     be  <font color="blue">manufacture</font>d  for  <font color="blue">development</font>,  <font color="blue">following approval</font>, in commercial     quantities, in <font color="blue">compliance with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font>, and <font color="blue">at <font color="blue">competitive</font></font>     costs</td>
    </tr>
    <tr>
      <td>If  we  or  any  of  our  product <font color="blue">collaborators</font> or third-party     <font color="blue">manufacture</font>rs,  product  <font color="blue">packagers</font>, or labelers are unable to maintain     <font color="blue">regulatory</font> compliance, the FDA can impose <font color="blue">regulatory</font> sanctions, including,     among other things, refusal to approve a <font color="blue">pending application</font> for a new drug     or <font color="blue">biologic product</font>, or revocation of a pre-existing approval</td>
    </tr>
    <tr>
      <td>As a result,     our  business,  financial  condition, and results of <font color="blue">operations</font> may be     <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> <font color="blue">facility</font> is likely to be inadequate to produce sufficient     quantities  of  product  for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>We intend to rely on our     corporate <font color="blue">collaborators</font>, as well as contract <font color="blue">manufacture</font>rs, to produce the     large  quantities of drug material needed for <font color="blue">commercialization</font> of our     products</td>
    </tr>
    <tr>
      <td>We rely entirely on third-party <font color="blue">manufacture</font>rs for filling and     finishing services</td>
    </tr>
    <tr>
      <td>We will have to <font color="blue">depend on</font> these <font color="blue">manufacture</font>rs to deliver     material on a <font color="blue">timely basis</font> and to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If we     are unable to <font color="blue">supply sufficient</font> material on acceptable terms, or if we     should  <font color="blue">encounter delays</font> or <font color="blue">difficult</font>ies in our <font color="blue">relationships with</font> our     corporate <font color="blue">collaborators</font> or contract <font color="blue">manufacture</font>rs, our business, financial     condition, and results of <font color="blue">operations</font> may be <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [50]Table <font color="blue">of <font color="blue">Contents       </font></font>We  may  expand  our  own <font color="blue">manufacturing</font> capacity to <font color="blue">support commercial</font>     production of <font color="blue">active <font color="blue">pharmaceutical</font> ingredients</font>, or API, for our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>This will require substantial <font color="blue">additional</font> funds, and we will need     to hire and train <font color="blue">significant</font> numbers of employees and <font color="blue">managerial personnel</font>     to staff our <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Start-up costs can be large and scale-up entails     <font color="blue"><font color="blue">significant</font> risks</font> related to process <font color="blue">development</font> and <font color="blue">manufacturing</font> yields</td>
    </tr>
    <tr>
      <td>We may be unable to develop <font color="blue">manufacturing</font> <font color="blue">facilities</font> that are sufficient to     produce drug material for <font color="blue">clinical trials</font> or <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>In addition, we     may be unable to <font color="blue">secure adequate filling</font> and finishing services to support     our products</td>
    </tr>
    <tr>
      <td>As a result, our business, <font color="blue">financial condition</font>, and results of     <font color="blue">operations</font> may be <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>We  may  be  unable  to  obtain <font color="blue">key <font color="blue">raw materials</font></font> and supplies for the     <font color="blue">manufacture</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, we may face <font color="blue">difficult</font>ies     in developing or acquiring <font color="blue">production technology</font> and <font color="blue">managerial personnel</font> to     <font color="blue">manufacture</font> sufficient quantities of our <font color="blue">product <font color="blue">candidates</font></font> at reasonable     costs and in <font color="blue">compliance with</font> applicable quality assurance and <font color="blue">environment</font>al     <font color="blue">regulations</font> and <font color="blue">government</font>al permitting <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">clinical programs</font> are <font color="blue">discontinued</font>, we <font color="blue">may face costs</font> related     to the <font color="blue">unused capacity at</font> our <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We have large-scale <font color="blue">manufacturing</font> <font color="blue">operations</font> in Rensselaer, New York</td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font>a long-term <font color="blue">manufacturing</font> <font color="blue">agreement</font> with Merck, <font color="blue">which expires</font> in <font color="blue">October     </font>2006,  we produce an <font color="blue">intermediate</font> for a Merck <font color="blue">pediatric vaccine at</font> our     <font color="blue">facility</font> in Rensselaer, New York</td>
    </tr>
    <tr>
      <td>We also use our <font color="blue">facilities</font> to produce API     for our own clinical and preclinical <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>When we <font color="blue">no longer use</font> our     <font color="blue">facilities</font> to <font color="blue">manufacture</font> the Merck <font color="blue">intermediate</font> or if clinical <font color="blue">candidates</font>     are <font color="blue">discontinued</font>, we will have to <font color="blue">absorb overhead costs</font> and <font color="blue">inefficiencies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Certain  </font>of  our  <font color="blue">raw materials</font> are single-sourced from <font color="blue">third parties</font>;     third-party supply failures could <font color="blue"><font color="blue">adversely</font> affect</font> our ability to supply our     products</td>
    </tr>
    <tr>
      <td>Certain <font color="blue"><font color="blue">raw materials</font> necessary</font> for <font color="blue">manufacturing</font> and <font color="blue">formulation</font> of our     <font color="blue">product <font color="blue">candidates</font></font> are provided by single-source unaffiliated third-party     suppliers</td>
    </tr>
    <tr>
      <td>We  would  be  unable to obtain these <font color="blue">raw materials</font> for an     <font color="blue">indeterminate period</font> of time if these third-party single-source suppliers     were to cease or <font color="blue">interrupt production</font> or <font color="blue">otherwise fail</font> to supply these     materials or products to us for any reason, including due to <font color="blue">regulatory</font>     <font color="blue">requirements</font>  or  action,  due to adverse financial <font color="blue">development</font>s at or     <font color="blue">affecting</font> the supplier, or due to <font color="blue">labor shortages</font> or disputes</td>
    </tr>
    <tr>
      <td>This, in     turn, could <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our ability to <font color="blue">manufacture</font> our     <font color="blue">product <font color="blue">candidates</font></font> for use in <font color="blue">clinical trials</font>, <font color="blue">which could</font> <font color="blue">materially</font> and     <font color="blue"><font color="blue">adversely</font> affect</font> our business and future prospects</td>
    </tr>
    <tr>
      <td>Also, certain of the <font color="blue">raw materials</font> required in the <font color="blue">manufacturing</font> and the     <font color="blue">formulation</font>  of our clinical <font color="blue">candidates</font> may be <font color="blue">derived from biological</font>     sources, including mammalian tissues, bovine serum, and <font color="blue">human serum albumin</font></td>
    </tr>
    <tr>
      <td>There are certain European <font color="blue">regulatory</font> restrictions on using these biological     <font color="blue">source materials</font></td>
    </tr>
    <tr>
      <td>If we are required to substitute for these sources to     <font color="blue">comply with</font> European <font color="blue">regulatory</font> <font color="blue">requirements</font>, our clinical <font color="blue">development</font>     <font color="blue">activities</font> may be delayed or <font color="blue">interrupted</font></td>
    </tr>
    <tr>
      <td>Risks Related to Commercialization of Products       If  we  are  unable  to  establish  sales, marketing, and <font color="blue">distribution</font>     <font color="blue">capabilities</font>, or enter into <font color="blue">agreement</font>s with <font color="blue">third parties</font> to do so, we will     be unable to <font color="blue">successfully</font> market and <font color="blue">sell future products</font></td>
    </tr>
    <tr>
      <td>We have no sales or <font color="blue">distribution</font> personnel or <font color="blue">capabilities</font> and have only a     small staff with marketing <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain those     <font color="blue">capabilities</font>, either by developing our own <font color="blue"><font color="blue">organization</font>s</font> or <font color="blue">entering into</font>     <font color="blue">agreement</font>s with service providers, we will not be able to <font color="blue">successfully</font> sell     any products that we may obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for and bring to market     in the future</td>
    </tr>
    <tr>
      <td>In that event, we will not be able to generate <font color="blue">significant</font>     revenue, even if our <font color="blue">product <font color="blue">candidates</font></font> are approved</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font>     that we will be able to hire the <font color="blue">qualified sales</font> and <font color="blue">marketing personnel</font> we     need  or  that we will be able to <font color="blue">enter into marketing</font> or <font color="blue">distribution</font>     <font color="blue">agreement</font>s with third-party providers on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font>the terms of our <font color="blue">collaboration</font> <font color="blue">agreement</font> with sanofi-aventis, we currently     rely on sanofi-aventis for sales, marketing, and <font color="blue">distribution</font> of the VEGF     Trap  in  cancer  <font color="blue"><font color="blue">indication</font>s</font>,  should it be approved in the future by     <font color="blue">regulatory</font> authorities for marketing</td>
    </tr>
    <tr>
      <td>We will have to rely on a <font color="blue">third party</font>     or devote <font color="blue">significant</font> resources to develop our own sales, marketing, and     <font color="blue">distribution</font> <font color="blue">capabilities</font> for our other <font color="blue">product <font color="blue">candidates</font></font>, including the     VEGF Trap-Eye, and we may be <font color="blue">unsuccessful</font> in developing our own sales,     marketing, and <font color="blue">distribution</font> <font color="blue">organization</font></td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________    [51]Table <font color="blue">of <font color="blue">Contents       </font></font>Even if our <font color="blue">product <font color="blue">candidates</font></font> are approved for marketing, their commercial     success  is  highly  uncertain  because our <font color="blue">competitors</font> may get to the     marketplace before we do <font color="blue">with better</font> or <font color="blue">lower cost drugs</font> or the market for     our <font color="blue">product <font color="blue">candidates</font></font> may be too small to support <font color="blue">commercialization</font> or     sufficient <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>There is substantial <font color="blue">competition</font> in the <font color="blue">biotechnology</font> and <font color="blue">pharmaceutical</font>     industries from <font color="blue">pharmaceutical</font>, <font color="blue">biotechnology</font>, and <font color="blue">chemical companies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Many     </font>of our <font color="blue">competitors</font> have <font color="blue">substantially</font> greater research, preclinical and     clinical product <font color="blue">development</font> and <font color="blue">manufacturing</font> <font color="blue">capabilities</font>, and financial,     marketing, and human resources than we do</td>
    </tr>
    <tr>
      <td>Our smaller <font color="blue">competitors</font> may also     enhance their <font color="blue"><font color="blue">competitive</font> position</font> if they acquire or <font color="blue">discover patentable</font>     <font color="blue">inventions</font>,  form  <font color="blue">collaborative</font>  <font color="blue">arrangements</font>,  or  merge  with large     <font color="blue">pharmaceutical</font> companies</td>
    </tr>
    <tr>
      <td>Even if we achieve product <font color="blue">commercialization</font>, our     <font color="blue">competitors</font>  have  achieved,  and  may  continue  to  achieve, product     <font color="blue">commercialization</font> before our products are approved for marketing and sale</td>
    </tr>
    <tr>
      <td><font color="blue">Genentech </font>has an approved VEGF <font color="blue">antagonist</font>, Avastin^®(Genentech), on the     market for <font color="blue">treating <font color="blue">certain cancers</font></font> and many <font color="blue">different</font> <font color="blue">pharmaceutical</font> and     <font color="blue">biotechnology</font> companies are working to develop competing VEGF <font color="blue">antagonist</font>s,     including Novartis, Eyetech Pharmaceuticals, and Pfizer</td>
    </tr>
    <tr>
      <td>Many of these     molecules are farther along in <font color="blue">development</font> than <font color="blue">the VEGF Trap </font>and may offer     <font color="blue">competitive</font> <font color="blue">advantages</font> over our molecule</td>
    </tr>
    <tr>
      <td>Novartis has an ongoing phase 3     clinical <font color="blue">development</font> program evaluating an orally delivered VEGF tyrosine     <font color="blue">kinase inhibitor</font> in <font color="blue">different</font> <font color="blue">cancer settings</font></td>
    </tr>
    <tr>
      <td><font color="blue">Onyx Pharmaceuticals </font>and     Bayer have received <font color="blue">approval from</font> the FDA to market and sell the first oral     <font color="blue">medication</font> that targets tumor cell growth and new <font color="blue">vasculature</font> formation that     fuels the growth of tumors</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">marketing approval</font>s</font> for Genentech’s VEGF     <font color="blue">antagonist</font>, Avastin, and their extensive, ongoing clinical <font color="blue">development</font> plan     <font color="blue">for Avastin </font>in other cancer <font color="blue"><font color="blue">indication</font>s</font>, may make it more <font color="blue">difficult</font> for us     to <font color="blue">enroll patients</font> in <font color="blue">clinical trials</font> to support <font color="blue">the VEGF Trap </font>and to obtain     <font color="blue"><font color="blue">regulatory</font> approval</font> of <font color="blue">the VEGF Trap </font>in these <font color="blue">cancer settings</font></td>
    </tr>
    <tr>
      <td>This may     delay or impair our ability to <font color="blue">successfully</font> develop and <font color="blue">commercialize</font> the     VEGF Trap</td>
    </tr>
    <tr>
      <td>In addition, even if <font color="blue">the VEGF Trap </font>is <font color="blue">ever approved</font> for sale for     the treatment of <font color="blue">certain cancers</font>, it will be <font color="blue">difficult</font> for our drug to     <font color="blue">compete against</font> Avastin and the Onyx/Bayer <font color="blue">kinase inhibitor</font>, because doctors     and <font color="blue">patients will</font> have <font color="blue">significant</font> experience using these medicines</td>
    </tr>
    <tr>
      <td>In     addition, an oral <font color="blue">medication</font> may be <font color="blue">considerably less expensive</font> for patients     than a biologic <font color="blue">medication</font>, providing a <font color="blue">competitive</font> advantage to companies     that market <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>The  market  for  eye  diseases  is  also  very  <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>Novartis and <font color="blue">Genentech </font>are     <font color="blue">collaborating</font>  on  the <font color="blue">development</font> of a VEGF antibody fragment for the     treatment of wet AMD that is in phase 3 <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005,     <font color="blue">Genentech </font>announced that it filed an <font color="blue">application with</font> the FDA to market and     sell this VEGF inhibitor in <font color="blue">patients with wet</font> AMD In addition, it has been     reported that <font color="blue">ophthalmologists</font> are using a third-party reformulated version     of  Genentech’s approved VEGF <font color="blue">antagonist</font>, Avastin <font color="blue">with success</font> for the     treatment of wet AMD The <font color="blue">marketing approval</font> of the Eyetech/Pfizer VEGF     inhibitor and the potential off-label use of Avastin and approval of the     Novartis/<font color="blue">Genentech </font>VEGF antibody fragment make it more <font color="blue">difficult</font> for us to     <font color="blue">successfully</font> develop the VEGF Trap-Eye</td>
    </tr>
    <tr>
      <td>Even if the VEGF Trap-Eye is ever     approved for sale for the treatment of <font color="blue">eye diseases</font>, it will be <font color="blue">difficult</font>     for our drug to <font color="blue">compete against</font> the Eyetech/Pfizer drug and, if <font color="blue">approved by</font>     the FDA, the Novartis/<font color="blue">Genentech </font>VEGF inhibitor, because doctors and patients     will  have <font color="blue">significant</font> experience using these medicines</td>
    </tr>
    <tr>
      <td>Moreover, the     <font color="blue">relatively</font>  low  cost of therapy with Avastin in <font color="blue">patients with wet</font> AMD     presents a further <font color="blue">competitive</font> challenge in this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of highly <font color="blue">effective</font> FDA approved TNF-<font color="blue">antagonist</font>s such as     Enbrel^® (Amgen), Remicade^® (Centocor), and Humira^® (Abbott Laboratories),     and the IL-1 receptor <font color="blue">antagonist</font> Kineret^® (Amgen), and other marketed     therapies makes it more <font color="blue">difficult</font> to <font color="blue">successfully</font> develop and <font color="blue">commercialize</font>     the IL-1 Trap</td>
    </tr>
    <tr>
      <td>This is one of the reasons we <font color="blue">discontinued</font> the <font color="blue">development</font> of     the IL-1 Trap in adult rheumatoid arthritis</td>
    </tr>
    <tr>
      <td>In addition, even if the IL-1     Trap is <font color="blue">ever approved</font> for sale, it will be <font color="blue">difficult</font> for our drug to compete     against these FDA approved TNF-<font color="blue">antagonist</font>s in <font color="blue"><font color="blue">indication</font>s</font> where both are     useful because doctors and <font color="blue">patients will</font> have <font color="blue">significant</font> experience using     these <font color="blue">effective</font> medicines</td>
    </tr>
    <tr>
      <td>Moreover, in such <font color="blue"><font color="blue">indication</font>s</font> these approved     <font color="blue">therapeutic</font>s may offer <font color="blue">competitive</font> <font color="blue">advantages</font> over the IL-1 Trap, such as     requiring <font color="blue">fewer injections</font></td>
    </tr>
    <tr>
      <td>There  are both small molecules and <font color="blue">antibodies</font> in <font color="blue">development</font> by third     parties that are designed to block the synthesis of interleukin-1 or inhibit     the signaling of interleukin-1</td>
    </tr>
    <tr>
      <td>These drug <font color="blue">candidates</font> could                                         18       _________________________________________________________________    [52]Table <font color="blue">of <font color="blue">Contents       </font></font>offer <font color="blue">competitive</font> <font color="blue">advantages</font> over the IL-1 Trap</td>
    </tr>
    <tr>
      <td>The successful <font color="blue">development</font>     of  these  competing  molecules  could  delay or impair our ability to     <font color="blue">successfully</font> develop and <font color="blue">commercialize</font> the IL-1 Trap</td>
    </tr>
    <tr>
      <td>For example, we may     find it <font color="blue">difficult</font> to <font color="blue">enroll patients</font> in <font color="blue">clinical trials</font> for the IL-1 Trap if     the companies developing these competing interleukin-1 <font color="blue">inhibitors</font> commence     <font color="blue">clinical trials</font> in the same <font color="blue"><font color="blue">indication</font>s</font></td>
    </tr>
    <tr>
      <td>We are developing the IL-1 Trap for the treatment of a spectrum of rare     <font color="blue">diseases associated with mutations</font> in the CIAS1 gene</td>
    </tr>
    <tr>
      <td>These <font color="blue">rare genetic</font>     <font color="blue">disorders affect</font> a small group of people, estimated to be <font color="blue">between several</font>     hundred and a <font color="blue">few thousand</font></td>
    </tr>
    <tr>
      <td>There may be too few patients with these genetic     disorders to profitably <font color="blue">commercialize</font> the IL-1 Trap in this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>The successful <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font> will <font color="blue">depend on</font>     obtaining  coverage  and  <font color="blue">reimbursement</font> for use of these <font color="blue">products from</font>     third-party payers</td>
    </tr>
    <tr>
      <td>Sales of <font color="blue">bio<font color="blue">pharmaceutical</font></font> products largely <font color="blue">depend on</font> the <font color="blue">reimbursement</font> of     patients’ medical expenses by <font color="blue">government</font> health care programs and private     health  insurers</td>
    </tr>
    <tr>
      <td>Without the financial support of the <font color="blue">government</font>s or     third-party payers, the market for any <font color="blue">bio<font color="blue">pharmaceutical</font></font> <font color="blue">product will</font> be     limited</td>
    </tr>
    <tr>
      <td>These third-party payers increasingly challenge the price and     examine  the  cost-<font color="blue">effective</font>ness of products and services</td>
    </tr>
    <tr>
      <td><font color="blue">Significant     </font><font color="blue">uncertainty</font> exists as to the <font color="blue">reimbursement</font> status of any new <font color="blue">therapeutic</font>,     <font color="blue">particularly</font> if there exist lower-cost standards of care</td>
    </tr>
    <tr>
      <td>Third-party payers     may not <font color="blue">reimburse sales</font> of our products, which would harm our business</td>
    </tr>
    <tr>
      <td>Risk Related to Employees       We are <font color="blue">dependent on</font> our <font color="blue">key personnel</font> and if we <font color="blue">cannot recruit</font> and retain     leaders  in  our  research, <font color="blue">development</font>, <font color="blue">manufacturing</font>, and commercial     <font color="blue"><font color="blue">organization</font>s</font>, our business will be harmed</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent on</font> our <font color="blue">executive officers</font></td>
    </tr>
    <tr>
      <td>If we are not able to     retain any of these persons or our Chairman, our business may suffer</td>
    </tr>
    <tr>
      <td>In     particular, we <font color="blue">depend on</font> the services of P Roy Vagelos, MD, the <font color="blue">Chairman </font>    of our board of <font color="blue">directors</font>, Leonard Schleifer, MD, Ph</td>
    </tr>
    <tr>
      <td>D, our <font color="blue">President </font>and     Chief Executive Officer, George D Yancopoulos, MD, Ph</td>
    </tr>
    <tr>
      <td>D, our Senior Vice President, Preclinical Development and     Biomolecular Science, and Randall G Rupp, Ph</td>
    </tr>
    <tr>
      <td>There is intense <font color="blue">competition</font> in the <font color="blue">biotechnology</font>     industry  for  qualified  <font color="blue">scientists</font>  and  <font color="blue">managerial personnel</font> in the     <font color="blue">development</font>, <font color="blue">manufacture</font>, and <font color="blue">commercialization</font> of drugs</td>
    </tr>
    <tr>
      <td>We may not be able     to continue to attract and retain the <font color="blue">qualified personnel necessary</font> for     developing our business</td>
    </tr>
    <tr>
      <td>Risks Related to Our <font color="blue"><font color="blue">Common Stock</font> </font>      Our stock price is <font color="blue">extremely volatile</font></td>
    </tr>
    <tr>
      <td>There has been <font color="blue">significant</font> volatility in our stock price and <font color="blue">generally</font> in     the <font color="blue"><font color="blue">market price</font>s</font> of <font color="blue">biotechnology</font> companies’ securities</td>
    </tr>
    <tr>
      <td>Various factors     and <font color="blue">events may</font> have a <font color="blue">significant</font> impact on the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>These factors include, by way of example:         •  progress, delays, or adverse results in <font color="blue">clinical trials</font>;         •  <font color="blue">announcement</font> of <font color="blue">technological innovations</font> or <font color="blue">product <font color="blue">candidates</font></font> by us     or <font color="blue">competitors</font>;         •  <font color="blue">fluctuations</font> in our operating results;          •   public concern as to the safety or <font color="blue">effective</font>ness of our product     <font color="blue">candidates</font>;         •  <font color="blue">development</font>s in our relationship with <font color="blue">collaborative</font> partners;         •  <font color="blue">development</font>s in the <font color="blue">biotechnology</font> industry or in <font color="blue">government</font> regulation     of healthcare;         •  large sales of our <font color="blue">common stock</font> by our <font color="blue">executive officers</font>, <font color="blue">directors</font>,     or <font color="blue">significant</font> <font color="blue">shareholders</font>;                                         19       _________________________________________________________________    [53]Table <font color="blue">of <font color="blue">Contents       </font></font>    •  arrivals and <font color="blue">departures</font> of <font color="blue">key personnel</font>; and         •  general market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">trading price</font> of our <font color="blue">common stock</font> has been, and <font color="blue">could continue</font> to be,     subject  to  wide <font color="blue">fluctuations</font> in response to these and other factors,     including the sale or <font color="blue">attempted sale</font> of a large amount of our <font color="blue">common stock</font>     in the market</td>
    </tr>
    <tr>
      <td>Broad market <font color="blue">fluctuations</font> may also <font color="blue"><font color="blue">adversely</font> affect</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Future sales of our <font color="blue">common stock</font> by our <font color="blue">significant</font> <font color="blue">shareholders</font> or us may     depress our stock price and impair our ability to <font color="blue">raise funds</font> in new share     offerings</td>
    </tr>
    <tr>
      <td>A small number of our <font color="blue">shareholders</font> <font color="blue">beneficial</font>ly own a substantial amount of     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, our seven largest <font color="blue">shareholders</font>,     including sanofi-aventis, <font color="blue">beneficial</font>ly owned 47dtta0prca of our <font color="blue">outstanding shares</font>     of <font color="blue">Common Stock</font>, assuming, in the case of Leonard S Schleifer, MD Ph</td>
    </tr>
    <tr>
      <td>D,     our Chief Executive Officer, and P Roy Vagelos, MD, our Chairman, the     <font color="blue">conversion</font> of their <font color="blue">Class A Stock </font>into <font color="blue"><font color="blue">Common Stock</font> </font>and the exercise of all     options held <font color="blue">by them which</font> are <font color="blue">exercisable within</font> 60 days of <font color="blue">December </font>31,     2005</td>
    </tr>
    <tr>
      <td>As of that date, sanofi-aventis owned 2cmam799cmam552 shares of Common     Stock, representing approximately 5dtta2prca of the shares of <font color="blue"><font color="blue">Common Stock</font> </font>then     outstanding</td>
    </tr>
    <tr>
      <td>Under our stock purchase <font color="blue">agreement</font> with sanofi-aventis, through     <font color="blue">September </font>5, 2006, sanofi-aventis may sell no more than 250cmam000 of these     shares in any <font color="blue">calendar quarter</font></td>
    </tr>
    <tr>
      <td>After <font color="blue">September </font>5, 2006, sanofi-aventis may     sell  no more than 500cmam000 of these shares in any <font color="blue">calendar quarter</font></td>
    </tr>
    <tr>
      <td>If     sanofi-aventis,  or  our  other  <font color="blue">significant</font>  <font color="blue">shareholders</font> or we, sell     substantial  amounts  of our <font color="blue"><font color="blue">Common Stock</font> </font>in the <font color="blue">public market</font>, or the     <font color="blue">perception</font> that <font color="blue">such sales may</font> occur exists, the <font color="blue">market price</font> of our Common     Stock could fall</td>
    </tr>
    <tr>
      <td>Sales of <font color="blue"><font color="blue">Common Stock</font> </font>by our <font color="blue">significant</font> <font color="blue">shareholders</font>,     including sanofi-aventis, also might make it more <font color="blue">difficult</font> for us to raise     <font color="blue">funds by selling equity</font> or equity-related securities in the future at a time     and price that we deem <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>Our existing <font color="blue">shareholders</font> may be able to exert <font color="blue">significant</font> influence over     matters requiring <font color="blue">shareholder approval</font></td>
    </tr>
    <tr>
      <td>Holders of Class A Stock, who are <font color="blue">generally</font> the <font color="blue">shareholders</font> who purchased     their stock from us before our initial public offering, are entitled to ten     votes per share, while holders of <font color="blue"><font color="blue">Common Stock</font> </font>are entitled to <font color="blue">one vote per</font>     share</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, holders of <font color="blue">Class A Stock </font>held 4dtta2prca of all     shares of <font color="blue"><font color="blue">Common Stock</font> </font>and <font color="blue">Class A Stock </font>then outstanding, and had 30dtta3prca of     the <font color="blue">combined voting power</font> of all of <font color="blue"><font color="blue">Common Stock</font> </font>and <font color="blue">Class A Stock </font>then     outstanding</td>
    </tr>
    <tr>
      <td>These <font color="blue">shareholders</font>, if acting together, would be in a position     to <font color="blue">significant</font>ly influence the election of our <font color="blue">directors</font> and to effect or     prevent  certain  corporate  <font color="blue">transactions</font>  that  require  majority  or     <font color="blue">supermajority approval</font> of the <font color="blue">combined classes</font>, including mergers and other     business <font color="blue">combinations</font></td>
    </tr>
    <tr>
      <td>This may result in our company taking corporate     actions that you may not consider to be in your <font color="blue">best interest</font> and may affect     the price of our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005:         •  our <font color="blue">current officers</font> and <font color="blue">directors</font> <font color="blue">beneficial</font>ly owned 14dtta8prca of our     <font color="blue">outstanding shares</font> of <font color="blue">Common Stock</font>, assuming <font color="blue">conversion</font> of their Class A     Stock into <font color="blue"><font color="blue">Common Stock</font> </font>and the exercise of all options held <font color="blue">by such persons</font>     which are <font color="blue">exercisable within</font> 60 days of <font color="blue">December </font>31, 2005, and 33dtta6prca of the     <font color="blue">combined voting power</font> of our <font color="blue">outstanding shares</font> of <font color="blue"><font color="blue">Common Stock</font> </font>and Class A     Stock, assuming the exercise of all options held <font color="blue">by such persons</font> which are     <font color="blue">exercisable within</font> 60 days of <font color="blue">December </font>31, 2005; and          •   our  seven largest <font color="blue">shareholders</font> <font color="blue">beneficial</font>ly owned 47dtta0prca of our     <font color="blue">outstanding shares</font> of <font color="blue"><font color="blue">Common Stock</font> </font>assuming, in the case of Leonard S     Schleifer, MD, Ph</td>
    </tr>
    <tr>
      <td>D, our Chief Executive Officer, and P Roy Vagelos,     MD, our Chairman, the <font color="blue">conversion</font> of their <font color="blue">Class A Stock </font>into <font color="blue"><font color="blue">Common Stock</font> </font>    and the exercise of all options held <font color="blue">by them which</font> are <font color="blue">exercisable within</font>     60 days of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>In addition, these seven <font color="blue">shareholders</font> held     53dtta4prca of the <font color="blue">combined voting power</font> of our <font color="blue">outstanding shares</font> of <font color="blue"><font color="blue">Common Stock</font> </font>    and Class A Stock, assuming the exercise of all options held by our Chief     Executive Officer and our <font color="blue">Chairman </font>which are <font color="blue">exercisable within</font> 60 days of     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [54]Table <font color="blue">of <font color="blue">Contents       </font></font>  The anti-takeover effects of provisions of our charter, by-laws, and rights     <font color="blue">agreement</font>, and of New York corporate law, could deter, delay, or prevent an     <font color="blue">acquisition</font> or other “change in control” of us and could <font color="blue"><font color="blue">adversely</font> affect</font>     the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our amended and <font color="blue">restated certificate</font> of incorporation, our by-laws, our     rights <font color="blue">agreement</font> and the <font color="blue">New York Business Corporation Law </font><font color="blue">contain various</font>     provisions that could have the effect of delaying or preventing a change in     control of our company or our <font color="blue">management</font> that <font color="blue">shareholders</font> may consider     favorable or <font color="blue">beneficial</font></td>
    </tr>
    <tr>
      <td>Some of these provisions could discourage proxy     contests and make it more <font color="blue">difficult</font> for you and other <font color="blue">shareholders</font> to elect     <font color="blue">directors</font> and take other <font color="blue">corporate actions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could also</font>     limit the price that investors might be willing to pay in the future for     shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These provisions include:         •  <font color="blue">authorization</font> to issue “blank check” <font color="blue">preferred stock</font>, which is     <font color="blue">preferred stock</font> that can be created and issued by the board of <font color="blue">directors</font>     without prior <font color="blue">shareholder approval</font>, with rights senior to those of our     common <font color="blue">shareholders</font>;         •  a <font color="blue">staggered board</font> of <font color="blue">directors</font>, so that it would take <font color="blue">three successive</font>     <font color="blue">annual meeting</font>s to replace all of our <font color="blue">directors</font>;         •  a requirement that removal of <font color="blue">directors</font> may only be effected for cause     and only upon the <font color="blue">affirmative vote</font> of at least eighty percent (80prca) of the     <font color="blue">outstanding shares</font> entitled to vote for <font color="blue">directors</font>, as well as a requirement     that  any  <font color="blue">vacancy on</font> the board of <font color="blue">directors</font> may be <font color="blue">filled only by</font> the     remaining <font color="blue">directors</font>;          •   any  action required or permitted to be taken at any meeting of     <font color="blue">shareholders</font> may be <font color="blue">taken without</font> a meeting, only if, prior to <font color="blue">such action</font>,     all of our <font color="blue">shareholders</font> consent, the effect of which is to require that     <font color="blue">shareholder action may only</font> be taken at a <font color="blue">duly convened meeting</font>;         •  any <font color="blue">shareholder seeking</font> to bring business before an <font color="blue">annual meeting</font> of     <font color="blue">shareholders</font> must provide timely notice of this intention in writing and     <font color="blue">meet various</font> other <font color="blue">requirements</font>; and          •  under the New York Business Corporation Law, a plan of merger or     <font color="blue">consolidation</font> <font color="blue">of the Company </font>must be <font color="blue">approved by</font> two-thirds of the votes of     all  outstanding  <font color="blue">shares entitled</font> to <font color="blue">vote thereon</font></td>
    </tr>
    <tr>
      <td>See the risk factor     <font color="blue">immediately</font> above captioned “Our existing <font color="blue">shareholders</font> may be able to exert     <font color="blue">significant</font> influence over matters requiring <font color="blue">shareholder approval</font></td>
    </tr>
    <tr>
      <td>”       We have a <font color="blue">shareholder rights</font> plan <font color="blue">which could</font> make it more <font color="blue">difficult</font> for a     <font color="blue">third party</font> to acquire us without the support of our board of <font color="blue">directors</font> and     principal <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>In addition, many of our <font color="blue">stock options</font> issued under     our 2000 Long-Term Incentive Plan <font color="blue">may become fully vested</font> in <font color="blue">connection with</font>     a “change in control” of the Company, as defined in the plan</td>
    </tr>
  </tbody>
</table>